Literature DB >> 9630921

Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes.

J K Sherwood1, L Zeitlin, K J Whaley, R A Cone, M Saltzman.   

Abstract

Current methods for sexually transmitted diseases (STD) prophylaxis, which can be disruptive and inconvenient, must be used before each act of sexual intercourse, so a method that provides protection over the course of many acts is desirable. We used a mouse model of vaginally-transmitted herpes simplex virus 2 (HSV-2) infection to test polymeric controlled-release devices for sustained passive immunoprotection. Vaginal disks were prepared by dispersing a monoclonal antibody to HSV-2 (III-174) within a matrix of poly(ethylene-co-vinyl acetate); these disks released 2 to 40 micrograms/day of antibody into buffered water. When disks were placed in the vagina, large amounts of III-174 (5 to 3,000 ng) were recovered from the vaginal fluid over the next 8 days. Mice were vaginally challenged with 10 ID50 of HSV-2 either 3 or 7 days after disk placement; no mice receiving III-174 disks became infected, while 65% of control mice receiving identical disks with nonspecific IgG did. Controlled-release disks with III-174 provided significant protection against HSV-2 infection (p < 0.005). This new technology for long-term STD prophylaxis should increase user compliance, a factor limiting the efficacy of current methods.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9630921     DOI: 10.1038/nbt0496-468

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  12 in total

Review 1.  Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions.

Authors:  A M Minnis; N S Padian
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

2.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.

Authors:  Samuel K Lai; D Elizabeth O'Hanlon; Suzanne Harrold; Stan T Man; Ying-Ying Wang; Richard Cone; Justin Hanes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-23       Impact factor: 11.205

3.  Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

4.  Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion.

Authors:  Alex Chen; Scott A McKinley; Simi Wang; Feng Shi; Peter J Mucha; M Gregory Forest; Samuel K Lai
Journal:  Biophys J       Date:  2014-05-06       Impact factor: 4.033

Review 5.  Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.

Authors:  Jill M Steinbach
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

6.  Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in Mucus.

Authors:  Timothy Wessler; Alex Chen; Scott A McKinley; Richard Cone; Gregory Forest; Samuel K Lai
Journal:  ACS Infect Dis       Date:  2015-10-17       Impact factor: 5.084

Review 7.  A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections.

Authors:  Valence M K Ndesendo; Viness Pillay; Yahya E Choonara; Eckhart Buchmann; David N Bayever; Leith C R Meyer
Journal:  AAPS PharmSciTech       Date:  2008-04-02       Impact factor: 3.246

Review 8.  Antibody-based concepts for multipurpose prevention technologies.

Authors:  Kevin J Whaley; Larry Zeitlin
Journal:  Antiviral Res       Date:  2013-11-01       Impact factor: 5.970

Review 9.  Immune Regulation of Antibody Access to Neuronal Tissues.

Authors:  Akiko Iwasaki
Journal:  Trends Mol Med       Date:  2017-02-07       Impact factor: 11.951

10.  B cells join T cell clusters in the host response to recurrent herpes simplex virus 2 infection.

Authors:  Jeff R Gehlhausen; Akiko Iwasaki
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.